CONTEXT: Commercial announcement of a joint initiative between Hoffmann-La Roche and BC Cancer along with Canadian Personalised Healthcare Innovation Network (CPHIN) to create an RWE framework in British Columbia to be known as the PRecision Oncology Evidence Development in Cancer Treatment (PREDiCT). The aim of the alliance is to generate and analyse RWE in order to help shape new sustainable reimbursement pathways for personalised cancer treatment.
IMPACT: Low
READ TIME: 2 mins
Quality Level Mean [1 – 10]: 7
1. “PREDiCT presents a great opportunity for BC Cancer to upgrade its molecular diagnostic offering to benefit more patients with clinically actionable information,” explains Dr. Stephen Yip, pathologist, BC Cancer and PREDiCT co-principal investigator.”
2. “Roche Canada Announces Collaboration to Improve Access to Personalized Healthcare with Real World Evidence.”
3. “This initiative is moving forward with the intent of operationalizing learning healthcare systems for life cycle health technology assessment, with a view to generate real-world evidence to make better informed decisions about treatment efficacy, patient value, and cost-effectiveness. “”
4. “” The ultimate goal is integrating a national framework to enable a more streamlined approach for patient access to cost-effective innovative treatments and technologies across many disease areas.”
5. “” Through this public-private partnership, PREDiCT paves the way for Canada-wide use of RWE at the healthcare decision-making level and unlock data insights that could lead to better patient outcomes.”